Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, randomized control phase II trial, to compare the
efficacy and safety of sintilimab combined with anlotinib versus standard platinum-based
chemotherapy as a first-line treatment in advanced NSCLC patients without driven-gene
mutations.